Healthcare
Live Price
Offline$25.81
+0.00% today
1Y Change
+14.70%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Koninklijke Philips N.V. (RYLPF) is a Healthcare stock with a market cap of $21.62B and listed on OTC. The stock last traded around $25.81 and up 14.7% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -1.1%, EPS growth of +225.3%, a dividend yield of 3.7%. What stands out right now is revenue -1.1%, EPS +225.3%, free cash flow +1.1% with operating margin 8.6% and ROIC 5.7%. The dividend matters to the case here, with a current yield around 3.7%. Valuation is more restrained than many high-expectation growth names at P/E 24.2 and price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RYLPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RYLPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RYLPF Max Drawdown
-22.90%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RYLPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.2B
-3.8% YoY
FY Net Income
$3.3B
+306.4% YoY
Free Cash Flow
$866.0M
+188.5% YoY
Revenue Growth
-1.1%
EPS Growth
+225.3%
Gross Margin
45.2%
Net Margin
5.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17.8B | 18.0B | 18.2B | 17.8B | 17.2B |
| Gross Profit | 8.1B | 7.8B | 7.4B | 7.2B | 7.2B |
| Operating Income | 1.6B | 529M | -115M | -1.5B | 553M |
| EBITDA | 2.7B | 2.3B | 1.0B | 115M | 2.0B |
| Net Income | 896M | -702M | -466M | -1.6B | 3.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.8B | 2.4B | 1.9B | 1.2B | 2.3B |
| Total Assets | 26.9B | 29.0B | 29.4B | 30.7B | 31.0B |
| Total Liabilities | 16.0B | 16.9B | 17.3B | 17.4B | 16.5B |
| Shareholder Equity | 11.0B | 12.0B | 12.0B | 13.2B | 14.4B |
| Total Debt | 8.1B | 7.5B | 7.6B | 8.2B | 7.0B |
| Net Debt | 5.3B | 5.1B | 5.7B | 7.0B | 4.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.6B
+1041.6% YoY
Capital Expenditures
763M
+5.3% YoY
Free Cash Flow
866M
+188.5% YoY
Key ratios
Gross Margin
45.2%
Operating Margin
8.6%
Net Margin
5.0%
ROE
8.2%
Debt / Equity
0.74x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.